Clinical application of recombinant erythropoietin in anemic cancer patients.
Anemia is common in cancer patients and may require treatment for symptomatic palliation. Transfusion has been the mainstay of therapy, but is not without risk. Because erythropoietin levels in cancer-related anemia are inadequate for the degree of anemia, recombinant human erythropoietin has been studied to treat the anemia. Results from these studies are encouraging.
Henry
D H
DH
Department of Medicine, University of Pennsylvania School of Medicine, Graduate Hospital Division of Hematology/Oncology, Philadelphia.
D000740:Anemia / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000191:economics; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin